Related references
Note: Only part of the references are listed.High-dose chemotherapy followed by autologous stem cell rescue in Wilms tumors: French report on toxicity and efficacy
Manon Delafoy et al.
PEDIATRIC BLOOD & CANCER (2022)
To transplant, or not to transplant? That is the question. A patient advocate evaluation of autologous stem cell transplant in neuroblastoma
Nicholas Bird et al.
PEDIATRIC BLOOD & CANCER (2022)
Clonal hematopoiesis and therapy-related myeloid neoplasms following neuroblastoma treatment
Tim H. H. Coorens et al.
BLOOD (2021)
Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) plus Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032
Alice L. Yu et al.
CLINICAL CANCER RESEARCH (2021)
Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission
Jaume Mora et al.
PEDIATRIC BLOOD & CANCER (2021)
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
Ruth Ladenstein et al.
CANCERS (2020)
The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive Studies
Jaume Mora et al.
FRONTIERS IN PHARMACOLOGY (2020)
Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma A Randomized Clinical Trial
Julie R. Park et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
High Dose Chemotherapy with Autologous Stem Cell Transplantation in Hepatoblastoma does not Improve Outcome. Results of the GPOH Study HB99
Beate Haeberle et al.
KLINISCHE PADIATRIE (2019)
High-dose treatment for malignant rhabdoid tumor of the kidney: No evidence for improved survivalThe Gesellschaft fur Padiatrische Onkologie und Hamatologie (GPOH) experience
Rhoikos Furtwaengler et al.
PEDIATRIC BLOOD & CANCER (2018)
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial
Ruth Ladenstein et al.
LANCET ONCOLOGY (2018)
Humanized 3F8 Anti-G(D2) Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma A Phase 1 Clinical Trial
Brian H. Kushner et al.
JAMA ONCOLOGY (2018)
Irinotecan-temozolomide with temsirolimus or dinutuximab Crosstafark in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial
Rajen Mody et al.
LANCET ONCOLOGY (2017)
MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy
Brian H. Kushner et al.
ONCOTARGET (2017)
Autologous hematopoietic stemcell transplantation following high-dose chemotherapy for nonrhabdomyosarcoma soft tissue sarcomas
Frank Peinemann et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2017)
Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin
Brian H. Kushner et al.
ONCOTARGET (2016)
High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma
Bilgehan Yalcin et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2015)
American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes
Lee M. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Secondary malignant neoplasms after high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma
Alissa Martin et al.
PEDIATRIC BLOOD & CANCER (2014)
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial
Susan G. Kreissman et al.
LANCET ONCOLOGY (2013)
High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma
Bilgehan Yalcin et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2013)
Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-Cis-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission
Nai-Kong V. Cheung et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Interval compressed vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide, etoposide in patients with advanced Ewing's and other Small Round Cell Sarcomas
Jeremy Whelan et al.
CLINICAL SARCOMA RESEARCH (2012)
High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation for Metastatic Rhabdomyosarcoma-A Systematic Review
Frank Peinemann et al.
PLOS ONE (2011)
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma.
Alice L. Yu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study
Katherine K. Matthay et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Long-term Outcomes in Survivors of Neuroblastoma: A Report From the Childhood Cancer Survivor Study
Caroline Laverdiere et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Stem cell transplantation for neuroblastoma
J. D. Fish et al.
BONE MARROW TRANSPLANTATION (2008)
Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system
BH Kushner et al.
BONE MARROW TRANSPLANTATION (2006)
Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial
F Berthold et al.
LANCET ONCOLOGY (2005)
High dose melphalan in the treatment of advanced neuroblastoma: Results of a randomised trial (ENSG-1) by the European neuroblastoma study group
J Pritchard et al.
PEDIATRIC BLOOD & CANCER (2005)
Long-term risk of second malignant neoplasms after neuroblastoma in childhood:: Role of treatment
C Rubino et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Phase II trial of the anti-GD2 monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma
BH Kushner et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults
BH Kushner et al.
BONE MARROW TRANSPLANTATION (2001)
High-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (ASCT) as salvage therapy for relapsed osteosarcoma
A Sauerbrey et al.
BONE MARROW TRANSPLANTATION (2001)
Share Paper
